ArticleCureus2025
Effects of Dexmedetomidine on Delirium in Trauma Intensive Care Unit (ICU) Patients: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background While some studies suggest that dexmedetomidine is a strong prophylactic against delirium, there is a lack of compelling evidence supporting its use in critically ill patients who have suffered traumatic injuries requiring treatment in intensive care settings. The primary objective of this study was to evaluate the effect of dexmedetomidine on the incidence of delirium in trauma ICU patients. Given the absence of a significant association, a secondary analysis was conducted to identify independent predictors of delirium. Methods A retrospective cohort study was conducted among adult patients with traumatic injuries admitted to the surgical-trauma ICU at a level 1 trauma center between 2017 and 2021. Level 1 trauma centers serve as regional referral centers, often managing the most severe and complex trauma cases. Patients were categorized into the dexmedetomidine-based sedation group (receiving dexmedetomidine along with other concomitant sedatives) and the non-dexmedetomidine-based sedation group (receiving other sedative agents, excluding dexmedetomidine). Results Of the 272 patients included in the study, 163 (60%) were in the dexmedetomidine-based sedation group. The incidence of delirium was comparable between dexmedetomidine-based and non-dexmedetomidine-based sedation groups (13.0% vs. 9.2%, p = 0.33). The risk of delirium was approximately threefold higher in patients with a pre-existing psychiatric illness (OR = 2.65, 95% CI 1.14-6.30, p = 0.02) and almost fourfold in patients with exposure to benzodiazepine (OR = 3.90, 95% CI 1.36-11.72, p = 0.02). Conclusions This study adds to the existing literature by presenting data on the incidence of delirium among trauma patients and assessing how dexmedetomidine affects its prevalence. The findings align with the current body of research, highlighting that pre-existing psychiatric conditions and benzodiazepine use are recognized risk factors for delirium in the trauma ICU population. Nevertheless, dexmedetomidine administration was not found to significantly influence the likelihood of developing delirium in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.